Kornimate/medical-research-clean huggingface dataset:
dynamic ctdna detection for colorectal cancer liver metastases

Conditions: Liver Metastases; Colorectal Cancer; Surgery; Circulating Tumor DNA; Minimal Residual Disease

Summary: evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort underwent curative resection after receiving multipoint ctdna detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.


Eligibility criteria:
inclusion criteria: 1. before implementing any trial-related procedures, written informed consent should be signed; 2. \>=20 and \<= 85 years old, male or female; 3. patients with liver metastases pathologically confirmed as colorectal adenocarcinoma; 4. according to the response evaluation criteria for solid tumors (recist version 1.1), there is at least one lesion that can be measured by imaging; 5. the multidisciplinary team (mdt) confirmed that the liver metastases were initially resectable ,without locally treatable extrahepatic metastases; 6. the general physical condition is good (ecog score 0-1); 7. life expectancy of more than 3 months; 8. there is no obvious symptoms of primary bleeding, obstruction and other indications for emergency surgery; 9. adequate organ function; 10. samples meet ngs quality control requirements; 11. the subjects are able and willing to comply with the visits, treatment plans, laboratory tests and other research-related procedures stipulated in the research protocol. exclusion criteria: 1. patients who are intolerant to systemic chemotherapy or surgery; 2. patients with multiple primary lesions; 3. blood samples and/or baseline tissue samples that do not meet the requirements for testing (hemolysis, low tumor cell content, insufficient dna extraction yield, etc.); 4. excessive tissue necrosis after conversion therapy, making it impossible to sample according to testing requirements 5. patients who have not undergone surgery after conversion therapy, only receiving radiofrequency ablation or chemotherapy follow-up 6. not all metastatic lesions were resected after conversion therapy, or liver metastatic lesions did not achieve r0 resection 7. no definite mutations detected in the tissue, or mutations detected in tumor tissue were not covered by the designed small panel.

Keywords: minimal residual disease colorectal liver metastases
integrating depression care in acute coronary syndromes care in china

Conditions: Acute Coronary Syndromes; Depression

Summary: the overall goal of this study is to develop, pilot test, implement, and evaluate a nurse-coordinated depression care model integrated into the care of acute coronary syndromes (acs) patients with rigorous assessment of feasibility, effectiveness, acceptability and cost in rural china. this study is a large multi-center, randomized clinical trial among 4,000 acs patients from 20 rural county hospitals selected from a well-established research network across china.


Eligibility criteria:
inclusion criteria: * age 20 to 79 years old * hospitalized due to a diagnosis of acute coronary syndromes (acs) * acs is stable (as judged by the treating cardiologist/internist) * signed patient informed consent exclusion criteria: * affected by severe cardiovascular disease or medical comorbidity that indicate the patient's life expectancy is less than 12 months (e.g. class iv heart failure, terminal cancer) * seriously disabled (unable to travel to the hospital, class iv heart failure at baseline) * suffering from problems that affect normal communication (e.g., intellectual impairment, observed mental confusion suggesting dementia, deafness, blindness, etc.) * non-permanent local residents or permanent residents planning to move out within 12 months * pregnant or breast-feeding or planning pregnancy within 12 months * affected by bipolar disorder, schizophrenia or severe depression that meet criteria for referral including patients with acutely suicidal risk (beck depression inventory item9=3) * having alcohol dependence (defined by mini alcohol dependence/abuse part)

Keywords: health services research acute coronary syndromes depression integrated care
pk/pd of caspofungin in children severe infection

Conditions: Pharmacokinetics; Infection, Fungal

Summary: caspofungin is an anti-fungal drug mainly metabolized by the liver. the pathophysiological status of children with severe infection will affect the metabolism of caspofungin in the body especially in the case of liver dysfunction. there is little metabolism of caspofungin through the kidney and continuous renal replacement therapy and renal function have little influence on the pharmacokinetics of caspofungin. the study aim to investigate pk/pd of caspofungin in children with specific pathophysiological conditions, such as liver insufficiency, hypoproteinemia, ecmo treatment, or sepsis.

the current international recommended dose of caspofungin is 70 mg per square metre for load for children who is older than three months of age, followed by 50 mg per square metre for maintenance. for newborns and infants younger than 3 months of age，25 mg per square metre is also recommended. whether such a recommended dose can achieve an ideal pk/pd target in children with liver insufficiency, hypoproteinemia, ecmo treatment, or severe infection is still lacking in sufficient clinical data. the objective of this study is to investigate pk/pd of caspofungin in children with specific pathophysiological conditions, such as liver insufficiency, hypoproteinemia, ecmo treatment, or sepsis. blood sampling time points of caspofungin are listed as follow: before administration (0 min); 1 h, 2 h, 4 h, 8 h , 12 h and 24 h after administration. the concentration of caspofungin in whole blood will be analyzed at huashan hospital of fudan university.

Eligibility criteria:
inclusion criteria: * children receiving caspofungin in pediatric intensive care unit exclusion criteria: * no informed consent signed participate in other clinical trials
detection of microplastics in human granulosa cells and in the follicular fluid of women undergoing icsi treatment

Conditions: Female Infertility; Environmental Exposure

Summary: plastic products have been used ubiquitously in the modern world for many decades - for example as packaging materials, textile fibers or molded parts. the general use and especially the improper disposal lead to enormous environmental pollution almost everywhere on earth. microplastics mainly originate from fragmentation of larger plastic objects or can be produced directly for the use in e.g. cosmetics or industrial dyes. microplastics have already been detected in fresh- and seawater, soil, food, but also in human blood and urine. the accumulation of microplastics in ovarian and testicular tissue in humans has not yet been investigated.

plastic products have been used ubiquitously in the modern world for many decades - for example as packaging materials, textile fibers or molded parts. the general use and especially the improper disposal lead to enormous environmental pollution almost everywhere on earth. in particular microplastics, by definition plastic particles with a diameter of less than 5mm, could pose a hazard to animals, humans and nature. microplastics mainly originate from fragmentation of larger plastic objects or can be produced directly for the use in e.g. cosmetics or industrial dyes. microplastics have already been detected in fresh- and seawater, soil, food, but also in human blood and urine. the accumulation of microplastics in ovarian and testicular tissue in humans has not yet been investigated. the presence of microplastics in reproductive tissue could also have negative consequences for reproduction. in oysters, waterfleas and mice, an impairment of reproduction due to the bioaccumulation of microplastics has already been described. overall, current understanding of the effects of microplastics on human fertility and overall mammalian health is very limited. samples will be analyzed using raman spectroscopy and scanning electron microscopy.

Eligibility criteria:
inclusion criteria: * the patients to be included should be ≥18 years of age undergoing an intracytoplasmic sperm injection (icsi) treatment. there is no upper limit for patient age. exclusion criteria: * none

Keywords: microplastics follicular fluid granulosa cells
corticosteroid nasal spray in covid-19 anosmia

Conditions: Covid19; Anosmia

Summary: the aim of this study is to evaluate the role of the topical corticosteroids nasal spray (mometasone furoate nasal spray) in improving anosmia in patients recovered from covid-19 infection.

this study willbe submitted on patients who recently recovered from proven covid-19 infection and complaining of anosmia or hyposmia.the proven covid-19 infection will be relied on a positive real-time reverse transcription polymerase chain reaction (rrt-pcr) with samples obtained by a nasopharyngeal swab. the recovery is defined as 2 consecutives negative (rrt-pcr) samples. complete medical history will be taken, and essential clinical assessment with appropriate protective measures will be performed in all patients.the patients in the study will be randomly divided into two groups: - group i: -who will receive topical corticosteroid nasal spray (mometasone furoate nasal spray) beside olfactory training group ii: -who will not receive topical corticosteroid nasal spray but only olfactory training. as regards the assessment of smell,the patient will assess his smell sensation using familiar substances with distinctive odor. a jar of coffee, a branch of mint and garlic are some used substances. the patient will report the degree of anosmia subjectively with score on a scale from 0 to 10.the assessment of smell will be done initially after recovery/discharge, after 1 week, 2 weeks and after 3 weeks for all patients. the duration of smell loss will be recorded from the onset of anosmia till full recovery of the sensation.

Eligibility criteria:
inclusion criteria: * adults 18 yrs or older patients * confirmed case (+ve pcr), * recovered/discharged (2 -ve pcr), * suffered from sudden recent anosmia or hyposmia exclusion criteria: * patients already on nasal steroid * with previous chronic rhinological pathologies, * patients on systemic steroid for previous systemic disease, * anosmia improved before covid19 recovery, * pregnancy * patients who will not complete the follow up period.

Keywords: covid19 anosmia mometasone nasal spray
use of injectable platelet rich fibrin in lichen planus

Conditions: Lichen Planus

Summary: platelet rich fibrine (prf), which promotes wound healing by supporting angiogenesis, immunity and epithelial proliferation phases. over a decade has since past since prf was developed and many clinicians now point to the potential use of a liquid version of prf. a liquid injectable-platelet-rich fibrin (i-prf) was developed by modifying spin centrifugation forces. at lower centrifugation speeds and by utilizing non-glass centrifugation tubes, the fibrin coagulation could be slowed down at early time points thus generating an injectable prf. much like traditional prf, i-prf contains an increase in leukocyte number and is further able to stimulate growth factor release. lichen planus is a common chronic mucocutaneous inflammatory disorder which generally affect s middle aged adults. therapeutic methods including topical and systemic corticosteroids for the treatment of oral lichen planus (olp) are suggested. however, long -term use of corticosteroids may be associated with local and systemic complications, and moreover, some patients may not be responsive. the investigators aimed to apply a treatment of autogenous origin (including no foreign products), considering the side effects of our corticosteroids. the study was designed as a split mouth. the investigators planned to administer i-prf to one side and intralesional corticosteroid therapy to the other side at patients with bilateral atrophic / erosive oral lichen planus lesions

lichen planus diagnosis will be made histopathologically. intraoral photographs and measurements will be taken at the beginning of the treatment and 2 months after the treatment is finished.

Eligibility criteria:
inclusion criteria: 1. oral erosive lesions were diagnosed according to andreasen classification. 2. histological confirmation of erosive olp according to the world health organization's clinicopathological diagnostic criteria for olp. 3. no previous treatment of oral lichen planus at least 3 months. 4. willingness and ability to complete the present clinical trial. 5. patients of ages above 18 years old without skin involvement. exclusion criteria: 1. histological signs of dysplasia. 2. using drugs associated with lichenoid reaction. 3. pregnant, lactating and smoker patients. 4. patient with systemic diseases such as diabetes mellitus, immunodysfunction, hematological and hepatological patients or had photosensitivity history.

Keywords: pain measurement platelet activation quality of life
platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (ad).

this is a multicenter, randomized, double-blind, placebo-controlled phase ii platform study to investigate the efficacy and safety of several interventions in participants with moderate to severe ad. the first intervention planned to be evaluated is ghz339. participants will be randomly assigned to one of the study arms.

Eligibility criteria:
key inclusion criteria of the master protocol: * able and willing to sign the informed consent (ic) * patients with a diagnosis of ad and onset of disease for at least 1 year * moderate to severe ad key exclusion criteria of the master protocol: * participants with a clinically significant medical condition or infectious disease (specified in sub-protocol) * participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ecg * participant with any other active inflammatory skin disease * participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension) * participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma) additional inclusion and exclusion criteria may apply depending on the intervention specific requirements

Keywords: atopic dermatitis dermatitis eczema moderate to severe
abdominal binder study to decrease postoperative pain

Conditions: Postoperative Pain

Summary: we conducted a controlled randomized trial examining the ability of the mott abdominal compression binder to decrease postoperative pain in gynecologic abdominal laparotomy patients


Eligibility criteria:
inclusion criteria: * gynecologic abdominal laparotomy patients exclusion criteria: * non gynecologic abdominal laparotomy patients

Keywords: abdominal binder
adjuvant hypofractionated radiotherapy for prostate cancer

Conditions: Prostate Cancer

Summary: hypofractionated radiation therapy is a new type of radiotherapy which has been shown to play a larger role in the treatment of prostate cancer. the aims of the trial were to evaluate the safety and feasibility of adjuvant hypofractionated radiotherapy following radical prostatectomy for prostate cancer.

the present study will be conducted as a prospective, prospective, single-centre, single-arm clinical trial. patients after radical prostatectomy with high-risk pathological factors will receive hypofractionated post-prostatectomy radiotherapy in 15 fractions. the primary endpoint of the study is incidence of radiotherapy-related gastrointestinal and genitourinary adverse events,judging by (ctcae)5.0. the secondary endpoints are progression-free survival (pfs) including biochemical recurrence-free survival (bpfs) and radiological progression-free survival (rpfs), economic evaluations, self-assessment of quality of life including abbreviated version of the expanded prostate cancer in-dex composite instrument (epic-26) and physical activity rank scale-3 (ars-3), overall survival (os) and prostate cancer-specific survival (css).

Eligibility criteria:
inclusion criteria: 1. ecog performance status 0-2. 2. pathologically confirmed prostate cancer and completion of radical prostatectomy. 3. postoperative pathological staging pt 3a, pt 3b, pt 4, surgical margins (+) or n1; or serum psa ≥0.1ng/ml at 6 weeks postoperatively; or serum psa \<0.1ng/ml at 6 weeks postoperatively, with two consecutive persistently elevated psa (≥0.1ng/ml) without signs of metastasis on clinical imaging (whole-body bone scan (ect), magnetic resonance imaging (mri), 68ga psma pet/ct, etc.) . 4. expected survival time \>5 years. 5. voluntarily accepted this experimental study protocol after being informed of the available treatment options. exclusion criteria: 1. patients with poor recovery of continence after radical prostatectomy. 2. patients with a history of pelvic and abdominal radiotherapy. 3. patients who participated in other clinical trials that were repugnant to the intervention of this trial within 4 weeks prior to the start of this trial. 4. patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (hiv) (+), hepatitis c virus (hcv) (+) and/or positive syphilis. 5. patients who are deemed unfit to participate in this clinical trial in the judgement of the investigator, for instance, patients with serious systemic diseases that, in the judgement of the investigator, may interfere with the treatment and evaluation of this trial and its compliance, including serious respiratory, circulatory, neurological, psychiatric, gastrointestinal, endocrine, immunological, urological and other systemic diseases. 6. patients with radiotherapy-related contraindications. 7. patients who cannot provide written informed consent and have poor adherence to treatment.
increasing resiliency among early post-treatment lymphoma survivors

Conditions: Lymphoma

Summary: the goal of this clinical trial is to learn if a mind body resilience group program can help increase lymphoma survivors' ability to cope with and manage the challenges that come with the transition into early post treatment survivorship.

this is a randomized controlled trial assessing the effects of the stress management and resiliency training: relaxation response resiliency-lymphoma (smart3rp-lymphoma) compared to enhanced usual care on 254 early post treatment lymphoma survivors. the smart-3rp is a comprehensive, evidence-based mind body group program designed to help individuals adapt to chronic stress (i.e., increase their resilience). it understands the adjustment to chronic stress as a dynamic process, blending cbt, positive psychology and mind body tools to target key coping processes. this trial seeks to answer the following questions: * will survivors randomized to smart3rp-lymphoma demonstrate greater improvements in coping skills when compared to survivors randomized to enhanced usual care? * do factors, such as age, sex, race/ethnicity, rural/urban living, socioeconomic status, impact how survivors respond to the treatment?

Eligibility criteria:
inclusion criteria: * english speaking adult (18 years or older at enrollment) * within 5 years of completing active, curative treatment for lymphoma (includes surgery, chemo-/immuno-/radiation therapy, or other) exclusion criteria: * active psychiatric or cognitive comorbidity as determined by site pi or treating clinician * unwilling or unable to participate using telehealth platform

Keywords: coping psychosocial intervention survivorship resilience
treatment of epiretinal membranes with ranibizumab

Conditions: Epiretinal Membrane

Summary: the purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.


Eligibility criteria:
inclusion criteria: * symptomatic idiopathic epiretinal membrane exclusion criteria: * vision worse than 6/18 and fit for surgery * prior vitreoretinal surgery or injection * diabetes * any past or current form of retinal vein occlusion or neovascularization * age-related macular degeneration * other condition causing significant limitation of visual potential
canakinumab in patients with covid-19 and type 2 diabetes

Conditions: Coronavirus Infection; Diabetes Mellitus, Type 2

Summary: the purpose of this study is to evaluate whether canakinumab has beneficial effects on patients with type 2 diabetes mellitus and coronavirus disease 19 (covid19).

patients with a metabolic syndrome (overweight, diabetes, hypertension) have a particularly bad outcome if infected with severe acute respiratory syndrome coronavirus 2 (sars-cov2). this may be explained by an over-activation of the interleukin-1 (il-1) beta system. metabolic stress (increased glucose and lipid levels) induces nod-, lrr- and pyrin domain-containing protein 3 (nlrp3) -mediated il-1beta secretion. sars-cov2 also activates nlrp3. therefore, the study proposes that metabolic stress in patients with overweight and diabetes potentiates covid-19 induced hyperinflammatory syndrome leading to excess mortality in these vulnerable patients. canakinumab (ilaris®) is a recombinant, human monoclonal antibody antagonizing il-1beta by blocking il-1beta activity. the aim of the study is to investigate the effect of canakinumab in type 2 diabetic patients with covid-19.

Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus * body mass index \> 25 kg/m² (overweight) * hospitalized with covid-19 exclusion criteria: * suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of covid-19 * treatment with immunomodulators or immunosuppressant drugs, including but not limited to tocilizumab, tumor necrosis factor (tnf) inhibitors and anti-il-17 agents within 5 half-lives or 30 days (whichever is longer) prior to randomization with the exception of anakinra which is excluded within 5 half-lives only. note: immunomodulators (topical or inhaled) for asthma and atopic dermatitis, and corticosteroids (any route of administration) such as dexamethasone are permitted. * history of hypersensitivity to canakinumab or to biologic drugs * neutrophil count \<1000/mm3 * pregnant or nursing (lactating) women * participation in another study with investigational drug within the 30 days preceding and during the present study-

Keywords: nlrp3 severe acute respiratory syndrome coronavirus 2 (sars-cov-2) coronavirus disease 19 (covid-19) il-1beta hyperinflammatory syndrome obesity